News and press releases

London, 15 May 2013 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) notes the press release issued today by the legal action charity Reprieve, regarding the potential use of its injectable phenobarbital for the purpose of capital punishment by the Arkansas Department of Corrections.

Phenobarbital is the world’s most widely used anti-convulsant. Hikma strongly objects to the use of any of its products in capital punishment. The Company is putting in place concrete steps to restrict the supply of its products for unintended uses. It has ceased the direct sale of injectable phenobarbital to US departments of corrections and will work directly with its distribution partners to add restrictions for unintended use to its distribution contracts.

Hikma aims to improve lives by providing patients with access to high quality, affordable medicines. Its medicines are used thousands of times a day to treat illness and save the lives of patients across its markets.

--  ENDS  --

Enquiries

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

Amman, 30 April 2013 – As part of Hikma Global Volunteering Campaign, Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, participated in INJAZ’s fourth “Young Volunteers Day”. Hikma organizes the global volunteering day annually across all its facilities worldwide aiming to encourage more employees at its different units to invest time in their local communities. This year, Hikma teamed up with INJAZ to spread the spirit of volunteerism among school students and Hikma employees to raise awareness about social responsibility and community service.

The activities of the program were held in sixteen schools in Salt, Sahab and different areas of Amman, where Hikma facilities are located, as part of Hikma’s commitment of giving back to the local community. On the 23rd and the 24th of April 2013, Hikma employees teamed up with 2200 students, from seventh to tenth grades, from the sixteen schools to get involved in various activities at their respective schools and communities. Activities revolved around community service, environment, and health and safety. They included meals preparation to those less fortunate, libraries’ renovation, cleaning, painting walls and planting trees at the school premises, in addition to health and safety awareness sessions such as traffic awareness and evacuation procedures in cases of fire and disasters.

Commenting on the volunteering day activities, Ms. Hana Ramadan, Vice President of Corporate Communications at Hikma Pharmaceuticals, said: “Hikma initiated its global volunteering day six years ago to allow its staff to take part in important and rewarding activities that help those less fortunate in their communities. Through our collaboration with INJAZ this year we are trying to spread out volunteerism spirit, raise awareness about social responsibility, support Jordan’s youth and enhance the educational environment among students”.

Mr. Fawaz Y. Salah the director of Inspirational & Career Guidance Program in INJAZ added: “Young Volunteer Day aims to instill the spirit of volunteerism in young people from an early age by engaging them in activities that directly benefit their schools. We are proud of our partnership with Hikma Pharmaceuticals, and their professional staff, for their commitment to invest in young people in our schools”.

INJAZ first started in 1999 as a USAID funded program and in 2001 it became an independent non-profit Jordanian organization under the patronage of Her Majesty Queen Rania Al Abdullah with the mission of inspiring and preparing young Jordanians to become productive members in their society and succeed in the global economy. Since its inception, INJAZ has successfully reached over 780,000 beneficiaries across the kingdom through its network of dedicated volunteers and its partners from the private, public, and civic society sectors. INJAZ is also a member of Junior Achievement Worldwide.

----- ENDS -----

London, 22 April 2013 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) today announces the signing of a licensing and distribution agreement with Dance Biopharm for its proprietary inhaled insulin product, Dance 01, for the Middle East and Africa. Dance 01 is currently under development for the treatment of patients with diabetes, with Phase 3 studies expected to begin next year.

Under the terms of the agreement, Hikma will have the exclusive rights to register, market and distribute Dance 01 across the Middle East and Africa.  The agreement will initially leverage Hikma’s strong local presence and regulatory expertise in the Middle East and North Africa (“MENA”), with over 1,600 sales and marketing representatives across the region.

Diabetes is a global epidemic, estimated to be affecting around 371 million patients worldwide.¹ In the MENA region, the private market for diabetes products was valued at over $668 million² in 2012, up 15% compared to 2011. Diabetes is the largest and fastest growing cause of morbidity in the MENA region and this agreement will enable patients in these countries to benefit from an innovative, easy-to-use insulin medication. Dance 01 will complement Hikma’s strong portfolio of prescription pharmaceuticals for the treatment of diabetes.

Said Darwazah, Hikma’s CEO said, "Hikma is committed to improving the treatment of diabetes in the MENA region through the development of our product portfolio.  We are extremely pleased to be partnering with Dance Biopharm in bringing this innovative treatment to the region, where we believe there is excellent market potential for inhaled insulin products.  This agreement supports our efforts in continuing to bring innovative and critically needed new products to our patients in MENA by working with a range of global partners at different stages in the product development cycle."

John Patton, Dance Biopharm’s CEO said, "Dance's mission is to bring affordable inhaled insulin to diabetes patients across the globe. We consider Hikma to be the most capable and well-positioned pharmaceutical partner in the MENA region, where the prevalence of diabetes is the highest in the world. Through this collaboration, Dance and Hikma will commercialise inhaled insulin in MENA as soon as possible."

----- ENDS -----

¹International Diabetes Federation Atlas, Fifth Edition
²IMS Health, YTD December 2012, private retail sales for the top nine MENA markets

Enquiries

About Dance Biopharm

Dance Biopharm is a San Francisco based, global company founded in 2009.  It is focused exclusively on creating a line of small, patient friendly, pain-free, low cost insulin inhalers for the world diabetes market.  Approximately 60% of Type 2 diabetic patients are out of glycemic control and many refuse to accept chronic mealtime injections.  Studies indicate that these patients strongly prefer inhaled insulin and would comply with recommended insulin therapy if inhaled.  Dance plans to leverage the extensive experience of their team, best in class technology and IP on inhaled insulin to produce low risk, fast to market products.

About Hikma

Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenue of US$1,108.7 million and profit attributable to shareholders of US$100.3 million.

London, 17 April 2013 – Further to its announcement of 1 March 2013 that it was undertaking a review of the strategic options for its global Injectables business, Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), the fast growing pharmaceutical group, today announces that it has concluded this strategic review and has determined that this business should remain part of the Hikma Group.

Hikma’s Board has noted the significant amount of interest shown in its Injectables business by third parties, demonstrating both the attractiveness of the global injectables market and the strength of Hikma’s business. 

The Board believes that Hikma is uniquely positioned to create significant further value by retaining this business and leveraging its high quality manufacturing facilities, broad product portfolio, attractive R&D pipeline and global distribution platform. Hikma’s Injectables business is performing very well and the Board is confident in management’s ability to continue to execute its Injectables growth strategy.

Said Darwazah, CEO of Hikma, said "After a thorough review of strategic options for the Injectables business, we are confident that retaining and continuing to invest in this business is the best option for shareholders.  Injectables offers excellent long-term growth prospects and will remain an integral part of our overall growth strategy.  By retaining the business, we will also continue to benefit from our diversified business model, which combines our global Injectables business with our oral generic business in the US and our extensive presence and experience in the Middle East and North Africa.”

----- ENDS -----

Enquiries

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,109 million and profit attributable to shareholders of $100 million.

London, 18 March 2013 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) today announces the signing of an exclusive ten-year collaboration and licensing agreement with Sinclair IS Pharma for Flammacerium, its leading hospital product for the prevention and treatment of infections from severe burn wounds, in the Middle East and North Africa (“MENA”) region.

Flammacerium is a sterile topical cream for the treatment and prevention of infections in extensive burn wounds.  The product is a silver sulfadiazine cream with cerium nitrate to reduce the occurrence of immunosuppression which can occur in severely burned patients.  Under the terms of the agreement, Hikma will have the exclusive rights to register and market Flammacerium in 18 countries across MENA.

Said Darwazah, Hikma’s CEO said, "A key part of our MENA strategy is to continue expanding our network of global alliances to support us in strengthening our product portfolio.  We are pleased to be partnering with Sinclair to bring Flammacerium, an excellent product which will strengthen our dermatology portfolio, to our patients in the MENA region."

Chris Spooner, CEO of Sinclair IS Pharma said, "This collaboration further demonstrates Sinclair’s ability to move our product portfolio into fast-growing emerging markets through regional partnerships.  Hikma’s presence and reputation across the MENA region will enable us to rapidly progress the adoption of Flammacerium."

--- ENDS ---

Enquiries

About Flammacerium

Flammacerium is a sterile topical cream for the treatment and prevention of infections in extensive burn wounds. The product is a silver sulfadiazine cream with cerium nitrate to reduce the occurrence of immunosuppression which can occur in severely burned patients.  It was approved in 1983 and is available in more than 50 countries.  Flammacerium does not have patent protection but barriers to entry limit competition.  It is used mainly in hospitals and specialist clinics.

About Sinclair IS Pharma

Sinclair IS Pharma is an international specialty pharmaceutical company centred on dermatology; in particular aesthetics, wound care, and skin care.  The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

About Hikma
Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenue of US$1,108.7 million and profit attributable to shareholders of US$100.3 million.

Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai:HIK), the fast growing multinational pharmaceutical group, today reports its preliminary results for the year ended 31 December 2012.